Angeli P, Albino G, Carraro P, Dalla Pria M, Merkel C, Caregaro L, De Bei E, Bortoluzzi A, Plebani M, Gatta A
Institute of Clinical Medicine, University of Padua, Italy.
Hepatology. 1996 Feb;23(2):264-73. doi: 10.1002/hep.510230211.
The aim of the study was to define the features, prevalence, and pathophysiology of therapy for muscle cramps in cirrhotic patients. The first protocol study included 294 cirrhotic patients and 194 age- and sex-matched controls. Controls were defined as inpatients or outpatients without any clinical and laboratory evidence of liver disease. Features and prevalence of muscle cramps were defined on the basis of a standard questionnaire. As far as the pathophysiological associations of muscle cramps were concerned, the following parameters were evaluated: mean arterial pressure (MAP), nutritional status, liver function tests, plasma volume (PV), plasma renin activity (PRA), and electrolyte, mineral, and acid-base status. The prevalence of cramps was higher in cirrhotic patients than in controls, and it was related to the duration of recognized cirrhosis and to the severity of liver function impairment. At a multiple regression analysis, the presence of ascites, low values of MAP, and high values of PRA were the independent predictive factors for the occurrence of cramps in cirrhosis. In the second protocol study, the effects of a sustained expansion of the effective circulating volume induced by intravenous infusion of human albumin were compared with those of a placebo in 12 cirrhotic patients with more than three cramp crises a week. Compared with the placebo, albumin reduced the cramp frequency (P < .01). In conclusion, an increased prevalence of true muscle cramps occurs in patients with cirrhosis. Our data indicate that the pathophysiological link between cirrhosis and cramps may be represented by the reduction of the effective circulating volume. They also indicate that weekly infusion of human albumin may be an effective treatment for cramps in cirrhosis.
本研究的目的是明确肝硬化患者肌肉痉挛的特征、患病率及治疗的病理生理学机制。首个方案研究纳入了294例肝硬化患者以及194例年龄和性别匹配的对照者。对照者定义为无任何肝病临床及实验室证据的住院患者或门诊患者。基于一份标准问卷确定肌肉痉挛的特征和患病率。就肌肉痉挛的病理生理关联而言,评估了以下参数:平均动脉压(MAP)、营养状况、肝功能检查、血浆容量(PV)、血浆肾素活性(PRA)以及电解质、矿物质和酸碱状态。肝硬化患者中痉挛的患病率高于对照者,且与已确诊肝硬化的病程及肝功能损害的严重程度相关。在多元回归分析中,腹水的存在、MAP低值以及PRA高值是肝硬化患者发生痉挛的独立预测因素。在第二个方案研究中,将静脉输注人白蛋白诱导有效循环血容量持续增加的效果与安慰剂对12例每周有超过三次痉挛发作的肝硬化患者的效果进行了比较。与人白蛋白相比,白蛋白降低了痉挛频率(P <.01)。总之,肝硬化患者中真正肌肉痉挛的患病率增加。我们的数据表明,肝硬化与痉挛之间的病理生理联系可能表现为有效循环血容量减少。数据还表明,每周输注人白蛋白可能是肝硬化患者痉挛的有效治疗方法。